Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Gastrointestinal Stromal Tumors 31Colorectal Neoplasms 12Pancreatic Neoplasms 11Carcinoma, Hepatocellular 11Stomach Neoplasms 8Neoplasms 7Liver Neoplasms 7Esophageal Neoplasms 6Carcinoma, Renal Cell 6Neoplasm Metastasis 5Gastrointestinal Neoplasms 5Adenoma, Islet Cell 5Neuroendocrine Tumors 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Prostatic Neoplasms 3Carcinoma 3Thyroid Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2Adenoma 2Adenocarcinoma Of Esophagus 2

Interventions

TH 302 2pasireotide 1omburtamab I-131 1gallium Ga 68 dotatate 1entinostat 1Thalidomide 1Sunitinib 1Radiotherapy, Image-Guided 1Nivolumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Sunitinib × Gastrointestinal × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡